• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure nabs reimbursement for Optune in Japan

December 1, 2017 By Sarah Faulkner

NovocureNovocure (NSDQ:NVCR) shares were up this morning after the Japanese Ministry of Health, Labour and Welfare agreed to reimburse for Optune as a treatment for newly-diagnosed glioblastoma.

The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. As a treatment for newly-diagnosed glioblastoma, Novocure combines its device with the anti-cancer drug temozolomide.

“Today marks an important milestone for Novocure in Japan,” Shungo Matori, Novocure’s GM for Japan, said in prepared remarks. “With reimbursement established, we will now turn our attention toward adoption of Optune in Japan.”

Novocure’s pivotal Phase III EF-14 trial compared the Optune-temozolomide combination to temozolomide alone in 695 patients with newly-diagnosed GBM. The study found that patients treated with Optune and temozolomide had a significant extension of overall survival, without added systemic toxicity, compared to patients treated with just temozolomide.

The data also showed that patients in the Optune group maintained their quality of life for a longer period of time compared to patients in the temozolomide alone.

Japan is the largest medical device market in which Novocure has landed government reimbursement for Optune as a therapy for newly-diagnosed GBM, the company said.

“Reimbursement in Japan demonstrates our dedication to expanding the geographic reach of our therapy and the acceptance of our therapy by an international government agency as a treatment that has been proven to extend survival in newly diagnosed GBM,” CEO Asaf Danziger added. “We remain committed to making our therapy available to all cancer patients who may benefit throughout the world.”

NVCR shares were trading at $19.70 apiece in mid-afternoon activity today, up 2.3%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS